Alembic Pharmaceuticals growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+10.1%	+9.1%
EBITDA	+10.9%	+16.4%
Net Income	+15.3%	+25.2%
EPS (adj.)	+15.7%	+25.4%
Total Assets	+12.7%	+12.3%
Total Equity	+9.2%	+9.1%
Free Cash Flow	—	+7.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

APLLTD₹794.85

Alembic Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersAJANTPHARM IPCALAB TORNTPHARM ALIVUS AKUMS AGARWALEYE ADVENZYMES AARTIPHARMMcap ₹15,623 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+10.1	+9.1
EBITDA	+10.9	+16.4
Net Income	+15.3	+25.2
EPS (adj.)	+15.7	+25.4
Total Assets	+12.7	+12.3
Total Equity	+9.2	+9.1
Free Cash Flow	—	+7.5

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.